The Citizens Charter for the Electronic Drug Price Monitoring System contains several steps and processes focused on certification and registration. To learn more about the Charter, please click on the link.
Republic Act No. 9502, otherwise known as the “Universally Accessible Cheaper and Quality Medicines Act of 2008,” mandated the Secretary of Health (SOH)to establish and initiate an electronic price monitoring and regulation system for drugs and medicines which is now known as the Electronic Drug Price Monitoring System (EDPMS).
Click the title to read more about the advisory.
The Department of Health will conduct series of virtual trainings on Antimicrobial Stewardship this August and October 2022.
The Department of Health informs all DOH and CHD officials, Philhealth and DOH hospitals and health facilities on the Exemption from Import Duties, Taxes and Other Fees for the Procurement, continue reading : DOH clarifies exemptions of COVID-19 Vaccines not listed under the latest PNF.
The Department of Health will hold a consultative meeting via Webex platform on 08 June 2022, 2:00-4:00 PM to get the comments and feedback of medical centers, hospitals, sanitaria and specialty hospitals on the newly-developed COVID-19 medicines tracker.
The Department of Health expressed elation over the signing of Executive Order (EO) No. 155, by President Rodrigo Roa Duterte adding 34 medicines to the list of drugs with mandatory price caps.
DOH informs the public of the adjustments in the Maximum Retail Price (MRP) of certain medicines that are covered by EO 155
The DOH reiterates the rational use of antimicrobials and investigational drugs for COVID-19 management
President Duterte inks executive order on new price cap of essential medicines
Access the full document Here
Guidelines on the Sponsorship of DOH in the Conduct of Clinical Trials for COVID-19 Investigational Products Related Posts Philippine Standard time Contact Us: Telephone Number: 02-8757734 Loc. 253 Address: 4th continue reading : (Administrative Order #2021-0052) Guidelines on the Sponsorship of DOH in the Conduct of Clinical Trials for COVID-19 Investigational Products